Regeneron Pharmaceuticals ... The other promising drug is in their growing oncology pipeline, as Zaltrap has given way to Libtayo, their treatment for metastatic melanoma. Libtayo was originally ...

Allow some time for an explanation There are two ways of looking at Regeneron. The sum-of-the-parts way and the platform way. Regeneron has 11 approved drugs but two comprise most of the cash flows.

We recently published a list of 11 Best Extremely Profitable Stocks to Buy According to Analysts. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Regeneron (REGN) to $1,081 from $1,150 and keeps an Overweight rating ...

Regeneron is to collaborate with Inovio to investigate a three-way immunotherapy combination against glioblastoma multiforme (GBM), an aggressive and hard-to-treat brain tumour. Regeneron’s drug ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition, with Eylea HD showing strong performance and new innovations like a pre-filled syringe on the horizon. Dupixent ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

With the FDA appearing to be undergoing major disruption under new leadership, BofA analyst Tim Anderson says one way to assess the risk from ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals ... which paved the way for RNA interference (RNAi) therapies like Fitusiran. Fitusiran has shown an impressive ...

Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses regulatory challenges for DB-OTO, Regeneron’s AAV-based gene therapy for hearing loss. Last month, Regeneron ...

Allow some time for an explanation There are two ways of looking at Regeneron. The sum-of-the-parts way and the platform way.